Exclusive Summary

• Backed by US-FDA GMP certification and US market registration, ensuring strict compliance with peak nitrosamine (NDMA) impurity limits as a highly credible and reliable supply source.
• Targets a massive baseline demand of over 1.28 billion hypertensive patients globally, serving as a first-line guideline-recommended drug with proven renoprotective benefits for diabetic nephropathy.
• Leverages cost-efficient Chinese manufacturing and offers a full range of strengths (75/150/300mg), providing overseas distributors with a high-margin generic product ideal for volume-based tenders and broad retail distribution.